TNG — Transgene SA Income Statement
0.000.00%
Last trade - 00:00
- €121.66m
- €107.35m
- €7.63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.3 | 9.34 | 17 | 10 | 7.63 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 38.8 | 33.3 | 40.5 | 39.9 | 37.7 |
Operating Profit | -25.5 | -24 | -23.5 | -29.9 | -30 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -18.8 | -17.2 | -19.5 | -32.8 | -22.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.8 | -17.2 | -19.5 | -32.8 | -22.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.8 | -17.2 | -19.5 | -32.8 | -22.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.8 | -17.2 | -19.5 | -32.8 | -22.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.229 | -0.206 | -0.214 | -0.33 | -0.222 |
Dividends per Share |